New Delhi: The Central Drugs Standard Control Organisation (CDSCO) has announced a total of 159 drug samples tested across the country during the month of June, 2026, as Not of Standard Quality (NSQ).
Out of the total samples that failed the tests, 27 were identified in the Central Drugs Laboratories, while 132 were identified by the State Drugs Testing Laboratories.
“Identification of drug samples as NSQ is done based on failure of the drug sample in one or the other specified quality parameters. The failure is specific to the drug products of the batch tested by the Government Laboratory and it does not warrant any concerns on the other drug products available in the market,” said the drug regulator.
During the month of April and May, 2026, two drug sample from Delhi were identified as spurious drugs, which was manufactured by unauthorized manufacturers using brand names owned by other companies. The drug regulator said that the matter is under investigation and action will be taken as per Act & Rules.
“This action of identifying NSQ and Spurious medicines is taken on regular basis in collaboration with state regulators to ensure that these drugs are identified and removed from of market,” added the drug regulator.
It may be noted that the CDSCO has declared 159 samples as NSQs during the month of May, 2026, out of which 113 samples were reported by the state laboratories. One drug sample from Assam was declared as spurious during the month, on which investigations have been announced by the drug regulator.
